Sugi Predict

Sugi Predict / Targets / ADCYAP1R1

ADCYAP1R1

Pituitary adenylate cyclase-activating polypeptide type I receptor · P41586 · ADCYAP1R1 on Sugi Atlas →

1,741 patent compounds predicted against ADCYAP1R1, 1,138 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2664645 SCHEMBL2664645 0.61 12/20
SCHEMBL2664165 SCHEMBL2664165 0.60 11/20
SCHEMBL2664459 SCHEMBL2664459 0.55 11/20
SCHEMBL2662809 SCHEMBL2662809 0.73 10/20
SCHEMBL2664243 SCHEMBL2664243 0.60 10/20
SCHEMBL2663822 SCHEMBL2663822 0.83 9/20
SCHEMBL2663729 SCHEMBL2663729 0.71 9/20
SCHEMBL7239651 SCHEMBL7239651 0.64 9/20
SCHEMBL7239653 SCHEMBL7239653 0.64 9/20
SCHEMBL9071579 SCHEMBL9071579 0.55 9/20
SCHEMBL2664431 SCHEMBL2664431 0.54 9/20
SCHEMBL2664423 SCHEMBL2664423 0.52 9/20
SCHEMBL2662671 SCHEMBL2662671 0.49 9/20
SCHEMBL2663992 SCHEMBL2663992 1.00 8/20
SCHEMBL2664615 SCHEMBL2664615 0.67 8/20
SCHEMBL2649190 SCHEMBL2649190 0.65 8/20
SCHEMBL2649191 SCHEMBL2649191 0.65 8/20
SCHEMBL2663841 SCHEMBL2663841 0.64 8/20
SCHEMBL2664213 SCHEMBL2664213 0.64 8/20
SCHEMBL2664209 SCHEMBL2664209 0.63 8/20

Clinical trials — most relevant to ADCYAP1R1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. PHASE2COMPLETED
Preoperative Bexarotene Treatment for Cushing's Disease PHASE1/PHASE2UNKNOWN
A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments PHASE2COMPLETED
A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine PHASE1COMPLETED
Effects of Hormone Stimulation on Brain Scans for Cushing s Disease EARLY_PHASE1COMPLETED
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow nanCOMPLETED
Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly nanUNKNOWN
The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients nanCOMPLETED
A Proof-of-concept Study Evaluating the Microbiota-gut-brain Axis nanRECRUITING
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load nanCOMPLETED
Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor nanCOMPLETED
How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors nanRECRUITING
PACAP27 Headache Properties in Migraine Without Aura Patients nanCOMPLETED
Genome-wide Association Study of Pituitary Tumors nanUNKNOWN
Prognosis of Atypical Pituitary Adenomas nanUNKNOWN
Application Research on Endoscopic Pseudocapsule-Based Resection for Pituitary Adenomas nanUNKNOWN
Inherited Reproductive Disorders nanRECRUITING
Hypersensitivity to PACAP-38 in Post-Traumatic Headache nanUNKNOWN
Asprosın And Tumor Necrosıs Factor-α Levels In Type 2 Dıabetıc Chronıc Periodontitis nanCOMPLETED
Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency nanCOMPLETED
Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38 nanNOT_YET_RECRUITING
Incidence of cCPHD in Denmark - a National Observational Study nanUNKNOWN
Clinical Characteristics and Analysis of Pituitary Complex and Rare Diseases nanRECRUITING
KLHL14 Expression as Predicting Factor of Invasiveness in pitNET nanCOMPLETED
Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CT nanRECRUITING
The Application of 68Ga-Pentixafor Alongside 68Ga-FAPI-04 PET/MR for Assessing Primary Aldosteronism. nanNOT_YET_RECRUITING
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders nanRECRUITING
Long Term Outcome Study in Patients With Pituitary Disorders nanACTIVE_NOT_RECRUITING
Differential Study of Invasive Pituitary Adenomas in the Sellar and Cavernous Sinus Regions nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a ADCYAP1R1 binder may also engage these)

ProteinNameSimilarity
Q29627 — 1.000 Q29627 →
VIPR2 Vasoactive intestinal polypeptide receptor 2 1.000 landscape →
P70205 — 0.999 P70205 →
P30083 — 0.999 P30083 →
Q63118 — 0.998 Q63118 →
Q9IB86 — 0.998 Q9IB86 →
P35000 — 0.996 P35000 →
Q68EK2 — 0.994 Q68EK2 →
P32215 — 0.994 P32215 →
Q28992 — 0.992 Q28992 →
GLP1R Glucagon-like peptide 1 receptor 0.991 landscape →
O08893 — 0.991 O08893 →
CALCR Calcitonin receptor 0.989 landscape →
Q0P4Y4 — 0.989 Q0P4Y4 →
SCTR Secretin receptor 0.989 landscape →
P41588 — 0.988 P41588 →
Q5FWI2 — 0.988 Q5FWI2 →
O35659 — 0.988 O35659 →
P79222 — 0.988 P79222 →
P97751 — 0.988 P97751 →
P35464 — 0.987 P35464 →
Q95NQ0 — 0.987 Q95NQ0 →
A6QP74 — 0.987 A6QP74 →
Q90308 — 0.986 Q90308 →
Q91085 — 0.985 Q91085 →
P23811 — 0.985 P23811 →
VIPR1 Vasoactive intestinal polypeptide receptor 1 0.985 landscape →
P83120 — 0.984 P83120 →
Q9GT50 — 0.984 Q9GT50 →
Q1LZF7 — 0.984 Q1LZF7 →